Search

Your search keyword '"Van Dyck K"' showing total 96 results

Search Constraints

Start Over You searched for: Author "Van Dyck K" Remove constraint Author: "Van Dyck K"
96 results on '"Van Dyck K"'

Search Results

1. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA a2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

5. Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

10. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States

11. 913 USING SHORT-TERM MONOTHERAPY AND IN VITRO DATA TO MAKE EARLY PREDICTIONS OF CLINICAL HCV RESPONSE: EXAMPLES FROM MK-5172, A SECOND GENERATION HCV NS3/4A PROTEASE INHIBITOR

13. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol

15. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

23. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.

26. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3

27. Magnetic resonance and computed tomography imaging of a carotid body tumor in a dog

29. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

30. A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants.

31. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

32. Microbial Interkingdom Biofilms and the Quest for Novel Therapeutic Strategies.

33. Adhesion of Staphylococcus aureus to Candida albicans During Co-Infection Promotes Bacterial Dissemination Through the Host Immune Response.

34. Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.

36. Bioluminescence Imaging to Study Mature Biofilm Formation by Candida spp. and Antifungal Activity In Vitro and In Vivo.

37. Candida albicans and Staphylococcus Species: A Threatening Twosome.

38. Inhibition of Vesicular Transport Influences Fungal Susceptibility to Fluconazole.

39. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

40. Essential oils and their components are a class of antifungals with potent vapour-phase-mediated anti-Candida activity.

41. Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test.

42. Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen.

43. Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.

44. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.

45. Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals.

46. A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel.

47. Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.

48. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.

49. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

50. Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model.

Catalog

Books, media, physical & digital resources